Mupirocin application at the exit site in peritoneal dialysis patients: Five years of experience

Renal Failure

Volumn 32, Issue 3, 2010, Pages 356-361

  Aykut, Sifil ^a   Caner, Cavdar ^a   Ozkan, Gungor ^b   Ali, Celik ^a   Tugba, Atay ^a   Zeynep, Gulay ^a   Taner, Camsari ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Exit site infection; Methicillin resistance; Mupirocin; Mupirocin resistance; Peritonitis

Indexed keywords

PSEUDOMONIC ACID;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PERITONITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORYNEBACTERIUM DIPHTHERIAE; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EXIT SITE INFECTION; FEMALE; GRAM NEGATIVE BACTERIUM; HEMODIALYSIS PATIENT; HUMAN; INFECTION; LONG TERM CARE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CATHETER-RELATED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUPIROCIN; PERITONEAL DIALYSIS; PERITONITIS;

EID: 77950573099     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003611703     Document Type: Article

References (20)

1. Keogh AM. Complications in peritoneal dialysis peritonitis and exit site infections. Perit Dial Int. 1996;16:S464-S467.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol. 1996;7:2176-2182. (Pubitemid 27468247)
3. Grupta B, Bernardini J, Piraino B. Peritonitis associated with exit site and tunnel infections. Am J Kidney Dis. 1996;28:415-419.
4. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, et al. Treatment of S. aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial. 1992;8:242-245.
5. Bernardini J, Piraino B, Holley J, Juhnston JR, Lutes R. A randomized trial of S. aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996; 27:695-700.
6. Chu KH, Choy WY, Cheung CC, et al. Prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Perit Dial Int. 2008;28:505-508.
7. Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant. 2010;25:587-592.
8. Ward A, Campoli-Richards DM. Mupirocin. A rewiew of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1986;32:425-444.
9. Mahajan S, Tiwari S, Kalra V, et al. Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population. Perit Dial Int. 2005;25:473-477. (Pubitemid 41448403)
10. Uttley L, Vardhan A, Mahajan S, Smart B, Hutchinson A, Gokal R. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit-site. J Nephrol. 2004;17:242-245. (Pubitemid 38779777)
11. Thodis E, Bhaskaran S, Passadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at catheter exit site. Perit Dial Int. 1998;18:261-270. (Pubitemid 28365117)
12. Cavdar C, Saglam F, Sifil A, et al. Effect of once-a-week vs thrice-a-week application of mupirocin on methicillin and mupirocin resistance in peritoneal dialysis patients: Three years of experience. Ren Fail. 2008;30:417-422. (Pubitemid 351868694)
13. Rosales M, Perez-Fontan M, Rodriguez-Carmona A, Garcia-Falcon T. Increasing resistance to mupirocin of S. aureus strains isolated from peritoneal dialysis patients and their partners: Long term study. Perit Dial Int. 2001;21:S218.
14. Peritoneal Dialysis-Related Infections Recommendations: 2005 Update. Perit Dial Int. 2005;25:107-131.
15. Casey M, Taylor J, Clinard P, et al. Application of mupirocin cream at the catheter exit site reduces exit cite infections and peritonitis in peritoneal dialysis patients. Perit Dial Int. 2000;20:566-568.
16. Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin- resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int. 2001;21:554-559. (Pubitemid 34083505)
17. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis. 2002;39:337-341. (Pubitemid 34174256)
18. Lobbedez T, Gardam M, Dedier H, et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: Still low after 7 years. Nephrol Dial Transplant. 2004;19:3140-3143. (Pubitemid 40057640)
19. Kesli R, Cander S, Celebi S. Fusidic acid resistance of S. aureus. Med J Kocatepe. 2004;5:33-36.
20. Lim CT, Wong KS, Foo MW. The impact of topical mupirocin on peritoneal dialysis infection rates in Singapore General Hospital. Nephrol Dial Transplant. 2005;20:2202-2206. (Pubitemid 41510098)